MA52235A - Anticorps anti-phf-tau et leurs utilisations - Google Patents
Anticorps anti-phf-tau et leurs utilisationsInfo
- Publication number
- MA52235A MA52235A MA052235A MA52235A MA52235A MA 52235 A MA52235 A MA 52235A MA 052235 A MA052235 A MA 052235A MA 52235 A MA52235 A MA 52235A MA 52235 A MA52235 A MA 52235A
- Authority
- MA
- Morocco
- Prior art keywords
- phf
- tau antibodies
- tau
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Plant Pathology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862638535P | 2018-03-05 | 2018-03-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA52235A true MA52235A (fr) | 2021-02-17 |
Family
ID=67767358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA052235A MA52235A (fr) | 2018-03-05 | 2019-03-04 | Anticorps anti-phf-tau et leurs utilisations |
Country Status (17)
Country | Link |
---|---|
US (2) | US10633435B2 (fr) |
EP (1) | EP3774888A4 (fr) |
JP (2) | JP7362636B2 (fr) |
KR (1) | KR20200130350A (fr) |
CN (1) | CN112105639A (fr) |
AU (1) | AU2019232631A1 (fr) |
BR (1) | BR112020018112A2 (fr) |
CA (1) | CA3093200A1 (fr) |
EA (1) | EA202092088A1 (fr) |
IL (1) | IL277075A (fr) |
JO (1) | JOP20200215A1 (fr) |
MA (1) | MA52235A (fr) |
MX (1) | MX2020009277A (fr) |
PH (1) | PH12020551373A1 (fr) |
SG (1) | SG11202008579UA (fr) |
TW (1) | TW201946654A (fr) |
WO (1) | WO2019171259A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3214310A1 (fr) | 2021-03-26 | 2022-09-29 | Rupesh Nanjunda | Anticorps anti-tau et leurs utilisations |
WO2023092004A1 (fr) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions et méthodes pour le traitement de troubles liés à tau |
TW202345899A (zh) * | 2022-03-11 | 2023-12-01 | 比利時商健生藥品公司 | 多特異性抗體及其用途(三) |
TW202346355A (zh) * | 2022-03-11 | 2023-12-01 | 比利時商健生藥品公司 | 多特異性抗體及其用途(二) |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US7408027B1 (en) * | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
EP0737208B1 (fr) * | 1993-12-21 | 2006-08-02 | Innogenetics N.V. | Anticorps monoclonaux specifiques de phf-tau, hybridomes les secretant, reconnaissance des antigenes par ces anticorps et leurs applications |
DE1250600T1 (de) * | 2000-01-24 | 2003-03-06 | Innogenetics Nv | Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau |
JP4619651B2 (ja) | 2001-06-01 | 2011-01-26 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | 前立腺特異的膜抗原に対する修飾抗体およびその使用 |
WO2004006955A1 (fr) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Anticorps super humanises |
US20050025763A1 (en) * | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
EP1697741A4 (fr) | 2003-12-04 | 2008-02-13 | Xencor Inc | Procedes pour produire des proteines variantes presentant une plus grande concentration en chaine hote et compositions de celles-ci |
DK2662390T3 (da) * | 2004-06-21 | 2017-11-06 | Squibb & Sons Llc | Interferon alpha receptor 1-antistoffer og anvendelse heraf |
EP1749839A1 (fr) * | 2005-07-22 | 2007-02-07 | Novoplant GmbH | Polypeptides de liaison d'antigènes F4 (K88) fimbriae |
WO2007064919A2 (fr) * | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Polypeptides de liaison avec des sequences de diversite limitees |
WO2009085462A1 (fr) | 2007-12-19 | 2009-07-09 | Centocor, Inc. | Conception et génération de banques d'exposition sur phage humain pix de novo au moyen d'une fusion vers pix ou pvii, vecteur, anticorps et procédés |
US20100261620A1 (en) | 2008-10-14 | 2010-10-14 | Juan Carlos Almagro | Methods of Humanizing and Affinity-Maturing Antibodies |
WO2011047146A2 (fr) | 2009-10-14 | 2011-04-21 | Centocor Ortho Biotech Inc. | Procédés de maturation d'affinité d'anticorps |
EP2621950A4 (fr) | 2010-09-27 | 2015-09-02 | Janssen Biotech Inc | Anticorps se liant au collagène humain de type ii |
SI2627672T1 (sl) * | 2010-10-11 | 2018-10-30 | Biogen International Neuroscience Gmbh | Človeška protitelesa anti-tau |
CN102457701B (zh) | 2010-11-02 | 2014-03-12 | 华为终端有限公司 | 图像显示处理方法及装置 |
US20140017242A1 (en) | 2010-12-03 | 2014-01-16 | Diamedica Inc. | Anti-bradykinin b2 receptor (bkb2r) monoclonal antibody |
EP3135689B1 (fr) * | 2011-10-07 | 2018-12-19 | AC Immune S.A. | Anticorps phosphospécifiques reconnaissant tau |
MY186066A (en) * | 2011-12-20 | 2021-06-18 | Janssen Biotech Inc | Anti-phf-tau antibodies and their uses |
EP3486256A3 (fr) * | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention B.V. | Anticorps et fragments de liaison à l'antigène qui se lient spécifiquement à la protéine tau associée aux microtubules |
WO2016112078A2 (fr) * | 2015-01-08 | 2016-07-14 | Janssen Biotech, Inc. | Anticorps tau/anti-phf et leurs utilisations |
TWI790642B (zh) | 2015-06-05 | 2023-01-21 | 美商建南德克公司 | 抗-tau抗體及使用方法 |
WO2017181098A2 (fr) * | 2016-04-15 | 2017-10-19 | Visterra, Inc. | Molécules d'anticorps se liant au virus zika et leurs utilisations |
TN2018000419A1 (en) * | 2016-07-12 | 2020-06-15 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof. |
US11834494B2 (en) * | 2016-07-26 | 2023-12-05 | Washington University | Antibodies to zika virus and methods of use thereof |
-
2019
- 2019-03-04 JO JOP/2020/0215A patent/JOP20200215A1/ar unknown
- 2019-03-04 CN CN201980030595.6A patent/CN112105639A/zh active Pending
- 2019-03-04 BR BR112020018112-9A patent/BR112020018112A2/pt unknown
- 2019-03-04 US US16/291,303 patent/US10633435B2/en active Active
- 2019-03-04 US US16/978,022 patent/US20210002358A1/en active Pending
- 2019-03-04 TW TW108107082A patent/TW201946654A/zh unknown
- 2019-03-04 AU AU2019232631A patent/AU2019232631A1/en active Pending
- 2019-03-04 MA MA052235A patent/MA52235A/fr unknown
- 2019-03-04 KR KR1020207028358A patent/KR20200130350A/ko unknown
- 2019-03-04 EA EA202092088A patent/EA202092088A1/ru unknown
- 2019-03-04 SG SG11202008579UA patent/SG11202008579UA/en unknown
- 2019-03-04 WO PCT/IB2019/051748 patent/WO2019171259A1/fr unknown
- 2019-03-04 MX MX2020009277A patent/MX2020009277A/es unknown
- 2019-03-04 EP EP19765110.2A patent/EP3774888A4/fr active Pending
- 2019-03-04 CA CA3093200A patent/CA3093200A1/fr active Pending
- 2019-03-04 JP JP2020546389A patent/JP7362636B2/ja active Active
-
2020
- 2020-09-01 IL IL277075A patent/IL277075A/en unknown
- 2020-09-02 PH PH12020551373A patent/PH12020551373A1/en unknown
-
2023
- 2023-10-04 JP JP2023172494A patent/JP2024009870A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US10633435B2 (en) | 2020-04-28 |
US20210002358A1 (en) | 2021-01-07 |
AU2019232631A1 (en) | 2020-09-24 |
MX2020009277A (es) | 2021-01-08 |
TW201946654A (zh) | 2019-12-16 |
US20190270793A1 (en) | 2019-09-05 |
JOP20200215A1 (ar) | 2020-09-03 |
JP2024009870A (ja) | 2024-01-23 |
WO2019171259A1 (fr) | 2019-09-12 |
IL277075A (en) | 2020-10-29 |
JP7362636B2 (ja) | 2023-10-17 |
PH12020551373A1 (en) | 2021-08-16 |
EP3774888A4 (fr) | 2021-12-29 |
SG11202008579UA (en) | 2020-10-29 |
BR112020018112A2 (pt) | 2020-12-22 |
CN112105639A (zh) | 2020-12-18 |
CA3093200A1 (fr) | 2019-09-12 |
EP3774888A1 (fr) | 2021-02-17 |
KR20200130350A (ko) | 2020-11-18 |
EA202092088A1 (ru) | 2020-11-13 |
JP2021515556A (ja) | 2021-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
MA49683A (fr) | Anticorps anti-cd8 et leurs utilisations | |
MA52773A (fr) | Anticorps anti-cd3 et leurs utilisations | |
MA46708A (fr) | Anticorps anti-pd1 et leurs utilisations | |
MA45235A (fr) | Anticorps anti-c5 et leurs utilisations | |
MA52949A (fr) | Anticorps anti-pd-1 et leurs utilisations | |
MA49687A (fr) | Anticorps anti-ctla-4 et leurs utilisations | |
MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
MA53168A (fr) | Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations | |
MA53184A (fr) | Anticorps anti-ox40 et leurs utilisations | |
MA52414A (fr) | Anticorps agonistes de pd-1 et leurs utilisations | |
MA52970A (fr) | Anticorps anti-psma x anti-cd28 bispécifiques et leurs utilisations | |
MA50144A (fr) | Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées | |
MA54539A (fr) | Anticorps anti-muc16 x anti-cd28 bispécifiques et leurs utilisations | |
MA50618A (fr) | Polyrhérapies et leurs utilisations | |
MA50397A (fr) | Anticorps anti-tau et leurs utilisations | |
MA52426A (fr) | Conjugués d'il-15 et leurs utilisations | |
MA42935A (fr) | Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations | |
MA52771A (fr) | Anticorps anti-cd33, anticorps bispécifiques anti-cd33/anti-cd3 et leurs utilisations | |
MA45233A (fr) | Anticorps anti-gitr et leurs utilisations | |
MA43567A (fr) | Anticorps pacap et leurs utilisations | |
MA44665A (fr) | Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques | |
MA52094A (fr) | Anticorps anti-il-27 et leurs utilisations |